Trial site

Valencia

Valencia, 46026, SpainNot linked to an institution yet

11running trials
16closed trials

The trials here

What the 27 trials at this site are about, from their registry records.

Conditions: Lung cancer6 trials
Colorectal cancer5 trials
Coronary artery disease3 trials
Melanoma3 trials
Multiple sclerosis3 trials
Chronic myeloid leukaemia2 trials
Chronic spontaneous urticaria2 trials
Familial hypercholesterolaemia2 trials
Prostate cancer2 trials
Stroke2 trials
Alzheimer disease1 trial
Epilepsy1 trial
and 10 more
Phase: Phase 315 trials
Phase 16 trials
Phase 23 trials
Phase 1/21 trial
Status: Completed12 trials
Active, not recruiting8 trials
Terminated4 trials
Recruiting3 trials
Lead sponsor: Novartis Pharmaceuticals27 trials

Running trials

Recruiting
A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
NCT07683065· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
NCT07570979· Phase 1· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
NCT07102628· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
NCT07094516· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT05838768· Phase 1· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04699188· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
NCT02962414· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Fatty liver disease (MASLD/MASH)1 recruiting
Multiple sclerosis1 recruiting
Prostate cancer1 recruiting
Psoriasis1 recruiting

Closed trials

Completed
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical Practice
NCT06251986· Novartis Pharmaceuticals· Source
Completed
A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks.
NCT05795153· Phase 3· Novartis Pharmaceuticals· Source
Completed
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
NCT05562934· Phase 2· Novartis Pharmaceuticals· Source
Completed
A Phase 3 Study of Efficacy and Safety of Remibrutinib in the Treatment of CSU in Adults Inadequately Controlled by H1 Antihistamines
NCT05030311· Phase 3· Novartis Pharmaceuticals· Source
Completed
Study of Diagnostic Performance of [18F]CTT1057 in BCR
NCT04838613· Phase 3· Novartis Pharmaceuticals· Source
Terminated
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301· Phase 3· Novartis Pharmaceuticals· Source
Completed
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· Phase 3· Novartis Pharmaceuticals· Source
Terminated
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
NCT04000529· Phase 1· Novartis Pharmaceuticals· Source
Completed
An Extension Study of Subcutaneous Secukinumab in Patients With Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA)
NCT03769168· Phase 3· Novartis Pharmaceuticals· Source
Completed
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
NCT03798626· Phase 1· Novartis Pharmaceuticals· Source
Completed
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
NCT03578367· Phase 2· Novartis Pharmaceuticals· Source
Terminated
A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma
NCT02974725· Phase 1· Novartis Pharmaceuticals· Source
Terminated
A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma
NCT02967692· Phase 3· Novartis Pharmaceuticals· Source
Completed
LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer
NCT01828099· Phase 3· Novartis Pharmaceuticals· Source
Completed
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
NCT01828112· Phase 3· Novartis Pharmaceuticals· Source
Completed
A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands
NCT01351103· Phase 1· Novartis Pharmaceuticals· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error